Abstract library

6 results for "Domenichini".
#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors: Pesce V, OConnor J, Mendez G, Bestani C, ...
#328 Report of Two First-Degree Relatives with Appendix Carcinoid and Review of the Literature
Introduction: Appendix endocrine tumors have an incidence of 2-3 patient/millon/year. They are more common in women, diagnosed incidentally during appendectomies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Claudia Bestani
#868 Role of 68Ga-DOTATATE PET/TC (68Ga-PET-CT) for the Management of Patients with Neuroendrocrine Tumors (NETs): Impact in Therapeutic Decisions of our Clinical Practice
Introduction: 68Ga-PET-CT has demonstrated a higher diagnostic accuracy than any other imaging procedures (CT/MRI/SRS). ARGENTUM group described their experience with 68Ga-PET-CT in eight patients with advanced Gastroenteropancreatic Neuroendocrine Tumors (ENETS 2011). Conclusion was that 68Ga-PET-CT enabled changes in the strategy of treatment in all cases. The impact of 68Ga-PET-CT on the therapeutic management in NETs is constantly under evaluation.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Claudia Bestani
#1147 Correlation of Serum Plasma Chromogranin A with Survival and Disease Features in Patients with Gastroenteropancreatic Neuroendocrine Tumors. First Results in a Large Database in Argentina. ARGENTUM GROUP.
Introduction: The plasma chromogranin A (CgA) is the best general biomarker in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). CrA levels are elevated in a variety of GEP-NETs and are used to aid in diagnosis, prognosis, and monitoring of treatment effects in this population.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Juan Manuel O'Connor
Authors: Belli S, O'Connor J M, Oneto A, Pesce V, ...
#1157 Cardiac Evaluation as Part of the Initial Extension Studies in Neuroendocrine Tumors. Experience in a Multidisciplinary Team. ARGENTUM GROUP
Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine tumors and is screened for using echocardiography. Published case series showed that when cardiological evaluation is done at least 50% of the patients have CHD, and 33% had surgical indication.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Juan Manuel O'Connor
#1159 Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract. ARGENTUM Group
Introduction: Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract are rare neoplasms. In the 2000 WHO classification of endocrine tumors, such neoplasms were defined as mixed exocrine-endocrine tumors when each component represents at least 30% of the lesion. In the most recent WHO classification, such neoplasms are called “mixed adenoneuroendocrine carcinomas” (MANECs). They are a challenge for the diagnostic and treatment.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Ana Cabanne
Keywords: MANEC, NETs